Open AccessOlanzapine-induced neuroleptic malignant syndrome in a patient with bipolar affective disorder: Does quetiapine holds the solution?
Author(s) -
Praveen Kumar Tripathi,
Hemika Agrawal,
Pankaj Goyal,
Sujita Kumar Kar
Publication year - 2013
Publication title -
industrial psychiatry journal/industrial psychiatry journal
Language(s) - English
Resource type - Journals
eISSN - 0976-2795
pISSN - 0972-6748
DOI - 10.4103/0972-6748.132934
Subject(s) - quetiapine , olanzapine , ziprasidone , neuroleptic malignant syndrome , amisulpride , aripiprazole , risperidone , clozapine , medicine , antipsychotic , atypical antipsychotic , haloperidol , paliperidone , psychiatry , schizophrenia (object oriented programming) , anesthesia , psychology , dopamine
Neuroleptic Malignant Syndrome (NMS) is a rare, severe and life threatening condition induced by antipsychotic medications. It is commonly encountered with the use of first generation antipsychotics, however cases of NMS have been reported with the use of second generation antipsychotics like Olanzapine, Risperidone, Paliperidone, Aripiprazole, Ziprasidone, Amisulpride, Quetiapine and Clozapine, though the incidence of such reports is rare. Due to decreased use of first generation antipsychotics, NMS is reported less frequently now a days. In this case report- we highlight the management issues of a patient suffering from bipolar affective disorder, who had developed NMS following intramuscular injection of haloperidol, which was withdrawn and olanzapine was given later on. The patient had again developed NMS with olanzapine. Finally the patient was managed with modified electroconvulsive therapy and discharged on Lithium carbonate and Quetiapine.